Protalix BioTherapeutics, Inc. (PLX)
| Market Cap | 175.65M -3.8% |
| Revenue (ttm) | 52.74M -1.2% |
| Net Income | -6.60M |
| EPS | -0.08 |
| Shares Out | 80.57M |
| PE Ratio | n/a |
| Forward PE | 10.14 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 407,159 |
| Open | 2.140 |
| Previous Close | 2.140 |
| Day's Range | 2.115 - 2.185 |
| 52-Week Range | 1.320 - 3.190 |
| Beta | -0.09 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+450.46%) |
| Earnings Date | May 8, 2026 |
About PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for PLX stock is "Strong Buy" and the 12-month stock price target is $12.0.
News
Protalix BioTherapeutics Earnings Call Transcript: Q4 2025
EU approval of Elfabrio's four-week dosing triggered a $25M milestone, boosting projected 2026 cash to $50M and supporting revenue growth over 50%. Pipeline advances in gout and renal indications, wit...
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EDT The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in adults living with Fabry disease...
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
Company to host conference call and webcast at 8:00 a.m. EDT CARMIEL, Israel, March 11, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the FDA-approve...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2...
Protalix BioTherapeutics Letter to Stockholders
CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization o...
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement
Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications Protalix i...
Protalix BioTherapeutics Earnings Call Transcript: Q3 2025
Nine-month revenues rose 24% year-over-year to $43.6 million, with Q3 net income of $2.4 million. PRX-115 phase II trial is set to begin soon, and cash reserves of $29.4 million are expected to fund o...
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
Company to host conference call and webcast today at 8:00 a.m. EST CARMIEL, Israel , Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focu...
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
Company to host conference call and webcast at 8:00 a.m. EST CARMIEL, Israel , Nov. 6, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on ...
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Protalix BioThera...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
-- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU -- -- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --
Why Is Protalix BioTherapeutics Stock Falling On Friday?
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion for Protalix BioTherapeutics, Inc.'s (NYSE:PLX) and Chiesi Group's partne...
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
Every two weeks remains approved as a dosing regimen of Elfabrio in the EU Every two weeks remains approved as a dosing regimen of Elfabrio in the EU
Protalix BioTherapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025
The presentation highlighted a unique plant cell technology platform, two approved drugs, and a promising pipeline asset for gout. Key catalysts include an EMA decision on monthly Elfabrio dosing and ...
Protalix BioTherapeutics to Present at Investor Summit Virtual
CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CARMIEL, Israel, Sept. 2, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombina...
Protalix BioTherapeutics Earnings Call Transcript: Q2 2025
Q2 2025 saw a 16% revenue increase and a return to profitability, driven by strong Elfabrio sales to Chiesi and reduced costs. R&D spending doubled in preparation for PRX-115 phase II, and the company...
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focu...
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on ...
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
CARMIEL, Israel , July 21, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombi...
Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®
CARMIEL, Israel , June 30, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombi...
Protalix BioTherapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
A unique plant cell-based biotech platform supports two approved drugs and a promising pipeline, with Elfabrio targeting significant Fabry market share and PRX-115 poised for a paradigm shift in gout ...
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
CARMIEL, Israel , May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombin...